T16	Exp 0 46	The tumour associated cell surface antigen A6H
T17	Exp 176 180	that
T18	Exp 102 129	The A6H monoclonal antibody
T19	Exp 286 297	The binding
T20	Exp 301 312	the A6H mAb
T21	Exp 398 400	we
T22	Exp 406 410	that
T23	Exp 378 396	the present report
T24	Exp 511 518	the CD8
T25	Exp 591 602	the A6H mAb
T26	Exp 730 758	these cell surface molecules
T27	Exp 875 877	we
T28	Exp 958 963	which
T29	Exp 809 819	the nature
T30	Exp 823 845	the A6H mAb costimulus
T31	Exp 849 874	the transcriptional level
T32	Exp 905 930	the transcription factors
T33	Exp 1066 1074	the IL-2
T34	Exp 1107 1122	the A6H antigen
T35	Exp 1127 1142	the CD3 complex
T36	Exp 1165 1194	the transcription factor AP-1
T37	Exp 1442 1446	that
T38	Exp 1504 1520	the later phases
T39	Exp 1419 1432	These results
T40	Exp 1580 1596	the A6H molecule
T41	Exp 1623 1630	the A6H
R3	Coref Anaphora:T17 Antecedent:T42
R4	Coref Anaphora:T28 Antecedent:T43
T1	Protein 74 77	CD4
T2	Protein 234 237	CD4
T3	Protein 483 486	CD4
T4	Protein 560 563	CD4
T5	Protein 615 619	CD80
T6	Protein 621 625	CD86
T7	Protein 627 631	CD71
T8	Protein 633 660	interleukin-2 (IL-2)R alpha
T9	Protein 662 672	IL-2R beta
T10	Protein 677 688	IL-2R gamma
T11	Protein 931 936	OCT-1
T12	Protein 1070 1074	IL-2
T13	Protein 1198 1201	CD4
T14	Protein 1679 1682	CD4
T42	Exp 147 175	a 120,000-140,000 MW antigen
T43	Exp 956 957	B
